Myricx Secures $114M Funding with Lilly’s Support for ADC Development

1. Funding Amount: Myricx, a London-based biotech, has raised $114 million in funding with support from Eli Lilly.
2. ADC Focus: The funding is focused on the development of Antibody-Drug Conjugates (ADCs), a promising area in biotech research.
3. Series A: Myricx was on the verge of raising its Series A funding in late 2021, indicating significant growth and investment in the company.
4. Lilly's Support: Eli Lilly's involvement in the funding highlights the company's interest in ADCs and its willingness to support innovative biotech ventures.
5. Recent Developments: The funding news comes amidst other significant biotech deals, including Lilly's acquisition of Morphic Therapeutic for $3.2 billion.